Hemoglobinuria clinical trials
The registry lists 14 studies for Hemoglobinuria across more than 10 countries. 2 are recruiting or about to start. 2 of them are mainly about Hemoglobinuria (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06.
Get an email when these change. Save the Hemoglobinuria studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Apellis Pharmaceuticals, Inc. (3) · Alexion Pharmaceuticals, Inc. (3) · Institute of Hematology & Blood Diseases Hospital, China (2) · St. Jude Children's Research Hospital (2) · Akron Children's Hospital (1) · International PNH Interest Group (1) · AO GENERIUM (1) · Yonsei University (1)
What is being tested here
Drugs under test in Hemoglobinuria studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Pegcetacoplan | 0 | 0 | 3 |
| Danicopan | 0 | 0 | 2 |
| Levamisole | 0 | 0 | 2 |
| Cyclosporine | 0 | 0 | 2 |
| Eculizumab | 0 | 1 | 1 |
| Fludarabine | 0 | 0 | 1 |
| Thiotepa | 0 | 0 | 1 |
| Melphalan | 0 | 0 | 1 |
| Mycophenolic Acid | 0 | 0 | 1 |
| Rituximab | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 1 Hemoglobinuria studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (100%) | 1 (100%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 14 studies, recruiting or not: 29% stop at 75 or younger and 21% at 65; 36% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 11, 2026.
Studies
Recruiting first, then most recently updated. Showing 14 of 14. search them.
- An Observational Post-Authorization Safety and Effectiveness Study of Ravulizumab in Adult Patients Aged 18 and Older Diagnosed With Paroxysmal Nocturnal Hemoglobinuria Using Multicenter Electronic Medical Records in South KoreaEnrolling by invitationNCT079218231 country
- The International PNH Interest Group PNH RegistryRecruitingNCT065247261 country
- Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure SyndromesCompletedNCT01192425
- A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT03181633Phase 23 countries
- Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT03053102Phase 24 countries
- Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNHCompletedNCT04463056Phase 31 country
- Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.CompletedNCT02588833Phase 14 countries
- A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNHCompletedNCT02264639Phase 11 country
- A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNHCompletedNCT03593200Phase 22 countries
- Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological MalignanciesCompletedNCT00566696Phase 21 country
- Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)Status unknownNCT01760096Phase 21 country
- Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal HemoglobinuriaStatus unknownNCT01642979Phase 21 country
- Haploidentical Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00186823Phase 31 country
- Incidence of Rhabdomyolysis Among Patients Admitted With Jimsonweed IngestionsCompletedNCT005926571 country